Frontlight ResearchEarly access
Chronic kidney disease trials in Belgium
10 of 14 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Where
- Aalst, Genk, Hasselt, Ieper, Jette, Kortrijk, Leuven, Liège, Mechelen, Namur, Roeselare, Ronse, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 5,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00 - Phase 3Taking peopleA Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Where
- Brasschaat, Genk, Hasselt, Ieper, Kluisbergen, Kortrijk, Leuven, Louvière, Mechelen, Ostend, Putte, Roeselare, Sint-Lambrechts-Woluwe
- Age
- 50 years and over
- People
- 7,140 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00 - No phaseTaking peopleStreamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
- Where
- Aalst, Bruges, Genk, Ghent, Liège
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Medtronic Vascular
See details and how to joinNCT07115953 - Phase 1Taking peopleStudy of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
- Where
- Ghent
- Age
- 18 years and over
- People
- 36
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07759167 · EU 2026-525844-14-00 - Phase 3Active, not recruitingA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Edegem, Leuven, Roeselare
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 3Active, not recruitingA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- Where
- Brussels, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 1 year to 18 years
- People
- 100 worldwide
- Run by
- Bayer
See details and how to joinNCT05457283 · EU 2023-504885-50-00 - Phase 2/3Taking peopleCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Where
- Aalst, Bonheiden, Charleroi, Ghent, La Louvière, Leper, Leuven, Liège, Roeselare, Sint-Niklaas
- Age
- 18 years and over
- People
- 3,110 worldwide
- Run by
- CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00 - Phase 3CompletedA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
- Where
- Gent
- Age
- 2 years to 17 years
- People
- 24 worldwide
- Run by
- Amgen
See details and how to joinNCT03969329 · EU 2023-506471-10-00 - No phaseTaking peopleBenefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate.
- Where
- Brussels
- Age
- 18 years and over
- People
- 50
- Run by
- Brugmann University Hospital
See details and how to joinNCT07413315 - No phaseTaking peopleEffect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation
- Where
- Brussels
- Age
- 18 years and over
- People
- 15
- Run by
- Universitair Ziekenhuis Brussel
See details and how to joinNCT07206524